{
  "ticker": "JNJ",
  "target_date": "2024-12-27",
  "actual_date": "2024-12-27",
  "collected_at": "2025-12-08T11:12:15.288038",
  "price": {
    "open": 140.57,
    "high": 142.25,
    "low": 140.38,
    "close": 140.74179077148438,
    "volume": 5588300,
    "change_1d_pct": -0.36,
    "change_7d_pct": -0.93,
    "change_30d_pct": -4.59
  },
  "technicals": {
    "rsi_14": 36.04,
    "sma_20": 143.34,
    "sma_50": 148.62,
    "macd": -2.353,
    "macd_signal": -2.477,
    "macd_histogram": 0.124,
    "bb_upper": 149.99,
    "bb_lower": 136.7,
    "price_vs_sma20_pct": -1.81,
    "price_vs_sma50_pct": -5.3,
    "volume_ratio": 0.65
  },
  "fundamentals": {
    "market_cap": 488918253568,
    "pe_ratio": 19.587837,
    "forward_pe": 19.144339,
    "price_to_book": 6.159286,
    "price_to_sales": 5.305736,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.35,
    "pct_from_52w_low": 44.25
  },
  "macro": {
    "spy": {
      "price": 589.84,
      "change_1d_pct": -1.05,
      "change_7d_pct": 1.83
    },
    "vix": {
      "level": 15.95,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.62
    },
    "dollar_index": {
      "level": 108.0
    },
    "gold": {
      "price": 2617.2
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal",
      "source": "Yahoo",
      "datetime": 1735334706,
      "summary": "Leerink keeps an Outperform rating and a $60 price target on Kymera Therapeutics (KYMR) while noting that the firm sees a \u201cpositive readthrough\u201d from the J&J\u2019s (JNJ) in-licensing of an oral STAT6 program from Kaken Pharmaceutical. Kymera has recently started a Phase 1 for STAT6 degrader KT-621, whil",
      "url": "https://finnhub.io/api/news?id=9424d1e9514cb7b34cf953d7d8d70d31096484fcbf2f7b02f06593c337243a2b"
    },
    {
      "headline": "Duvakitug And Teva's Growth: A Game Changer In Pharma",
      "source": "SeekingAlpha",
      "datetime": 1735312889,
      "summary": "Teva Pharmaceutical Industries continues to impress investors with strong sales growth and promising development. Click here to find out why TEVA is a Buy.",
      "url": "https://finnhub.io/api/news?id=f932524cce0ab7e6732fb2bdfb867eccfcc2050d50d49631a3b1c7b1033d3814"
    },
    {
      "headline": "JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723",
      "source": "Yahoo",
      "datetime": 1735301820,
      "summary": "Johnson & Johnson announces a global licensing deal with Kaken for the latter's eczema candidate, KP-723, to further strengthen its dermatology portfolio.",
      "url": "https://finnhub.io/api/news?id=8067715c298079202eff6aaf099e12e59df362ab2fe8c0ced03780a73220bd9a"
    },
    {
      "headline": "Johnson & Johnson to license novel oral assets, further strengthening commitment to atopic dermatitis",
      "source": "Finnhub",
      "datetime": 1735294335,
      "summary": "NEW BRUNSWICK - Johnson & Johnson1 announced today that it has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for...",
      "url": "https://finnhub.io/api/news?id=c7241da69da5d5fae267f5bfb004512301fd55b0d8846438fa4d87c9245ab1b7"
    },
    {
      "headline": "J&J: exclusive agreement with Karen Pharmaceutical",
      "source": "Finnhub",
      "datetime": 1735280591,
      "summary": "Johnson & Johnson announces that it has entered into an exclusive agreement with Kaken Pharmaceutical for the worldwide development, manufacture and commercialization of the STAT6 program for...",
      "url": "https://finnhub.io/api/news?id=79761049c9c716638097684cc8e4947e0cc969361bf1b690e5dacdacec040895"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734042449.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000106/xslF345X05/wk-form4_1734042449.xml"
    },
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734041779.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000104/xslF345X05/wk-form4_1734041779.xml"
    },
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734041373.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000102/xslF345X05/wk-form4_1734041373.xml"
    },
    {
      "form": "13F-HR",
      "date": "2024-11-13",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445424000604/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "10-Q",
      "date": "2024-10-23",
      "description": "jnj-20240929.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000096/jnj-20240929.htm"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}